IONS Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc. (IONS) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 97% planned / 3% discretionary
Largest single sale: $4.5M.
Where they traded
Last open-market purchase: July 31, 2026 , by Hayden Michael R .
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Hayden Michael R | Director | Buy | 5,000 | $51.60 | $258.0K | 24,000 | |
| Hayden Michael R | Director | Buy | 15,000 | $53.38 | $800.7K | 19,000 | |
| BENNETT C FRANK 2 fills | EVP, Chief Scientific Officer | Sell 10b5-1 | 20,536 | $84.95 | $1.7M | 75,018 −21.5% of holding | |
| Diaz Allene M. | Director | Sell 10b5-1 | 10,111 | $85.42 | $863.6K | 3,811 −72.6% of holding | |
| Kordasiewicz Holly B. | EVP, Chief Development Officer | Sell 10b5-1 | 362 | $84.30 | $30.5K | 22,096 −1.6% of holding | |
| KLEIN JOSEPH III 2 fills | Director | Sell 10b5-1 | 11,518 | $79.04 | $910.4K | 22,433 −33.9% of holding | |
| Monia Brett P | Chief Executive Officer | Sell 10b5-1 | 50,000 | $80.59 | $4.0M | 245,571 −16.9% of holding | |
| Schneider Eugene | EVP, Chf Clinical Develop Ofcr | Sell 10b5-1 | 26,000 | $81.05 | $2.1M | 77,114 −25.2% of holding | |
| Baroldi Joseph | EVP, Chief Business Officer | Sell 10b5-1 | 5,635 | $80.16 | $451.7K | 4,669 −54.7% of holding | |
| O'NEIL PATRICK R. | EVP CLO & General Counsel | Sell 10b5-1 | 3,069 | $80.00 | $245.5K | 61,470 −4.8% of holding | |
| Monia Brett P | Chief Executive Officer | Sell 10b5-1 | 21,072 | $78.49 | $1.7M | 245,571 −7.9% of holding | |
| Swayze Eric | EVP Research | Sell 10b5-1 | 10,602 | $79.18 | $839.5K | 21,759 −32.8% of holding | |
| Monia Brett P | Chief Executive Officer | Sell 10b5-1 | 14,565 | $78.41 | $1.1M | 245,571 −5.6% of holding | |
| BERTHELSEN SPENCER R | Director | Sell 10b5-1 | 8,000 | $73.49 | $587.9K | 156,013 −4.9% of holding | |
| Kordasiewicz Holly B. 2 fills | EVP, Chief Development Officer | Sell 10b5-1 | 60,846 | $73.41 | $4.5M | 42,300 −59% of holding | |
| BERTHELSEN SPENCER R | Director | Sell 10b5-1 | 8,000 | $75.67 | $605.4K | 156,013 −4.9% of holding | |
| Monia Brett P | Chief Executive Officer | Sell 10b5-1 | 3,220 | $78.68 | $253.3K | 242,662 −1.3% of holding | |
| Monia Brett P | Chief Executive Officer | Sell 10b5-1 | 1,316 | $78.01 | $102.7K | 242,662 −0.5% of holding | |
| LOSCALZO JOSEPH 2 fills | Director | Sell 10b5-1 | 77,289 | $75.06 | $5.8M | 54,111 −58.8% of holding | |
| KLEIN JOSEPH III 2 fills | Director | Sell 10b5-1 | 10,111 | $73.51 | $743.2K | 12,445 −44.8% of holding | |
| Baroldi Joseph | EVP, Chief Business Officer | Sell 10b5-1 | 1,626 | $71.79 | $116.7K | 44,909 −3.5% of holding | |
| Baroldi Joseph | EVP, Chief Business Officer | Sell | 5,619 | $74.56 | $419.0K | 46,535 −10.8% of holding | |
| Jenne Kyle | EVP, Chf GL Pdt Str Ofcr | Sell | 4,902 | $75.17 | $368.5K | 23,713 −17.1% of holding | |
| Birchler Brian | EVP, Corp and Development Ops | Sell | 973 | $75.04 | $73.0K | 67,500 −1.4% of holding | |
| PARSHALL B LYNNE 2 fills | Director | Sell 10b5-1 | 5,000 | $76.27 | $381.4K | 51,878 −8.8% of holding | |
| Devers Shannon L. | EVP, Chief Human Resources Ofc | Sell 10b5-1 | 6,193 | $74.05 | $458.6K | 16,348 −27.5% of holding | |
| KLEIN JOSEPH III 2 fills | Director | Sell 10b5-1 | 22,321 | $75.55 | $1.7M | 13,230 −62.8% of holding | |
| Schneider Eugene | EVP, Chf Clinical Develop Ofcr | Sell 10b5-1 | 5,812 | $70.97 | $412.5K | 63,890 −8.3% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.